COMPASS Pathways Plc - American Depository Shares (CMPS)
4.6800
-0.3100 (-6.21%)
COMPASS Pathways is a biotechnology company dedicated to advancing mental health treatment through innovative therapies
It focuses on developing psilocybin therapy, a novel approach to addressing conditions such as treatment-resistant depression. By conducting clinical trials and research, the company seeks to create evidence-based solutions that harness the potential of psychedelic substances in a controlled and therapeutic context. COMPASS Pathways aims to improve patient outcomes and transform mental health care through its pioneering work in the field of psychedelics and mental health.
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
